WASHINGTON – The actual number of COVID-19 instances in the United States can be 6 to 24 times higher than reported, according to a new review released Tuesday.
In the 16025 study of residual clinical samples, the U.S. Centers for Disease Control and Prevention (CDC) estimated that the proportion of others with detectable SARS-CoV-2 antibodies ranged from 1% in the San Francisco Bay Area to 6.9% in New York.
The test conducted serological tests on an appropriate pattern of residual serums received from others of all ages. The serum was collected from March 23 to May 12 for clinical testing of the regimen through two advertising lab companies.
“Our effects for each site recommend that the number of infections be much higher than the number of instances reported during the examination period,” the review, published in JAMA Internal Medicine, said.
For peak sites, more than 10 times more SARS-CoV-2 infections are likely to have occurred than the number of REPORTED COVID-19 cases. According to the study, most other people at the site probably did not have detectable antibodies opposite SARS-CoV-2.
According to the study, between six and 24 times more seroprevalence-compatible infections were estimated than with knowledge of COVID-19 case reports.